1. A pharmaceutical agent for use in treating inflammation in an individual prone and / or experiencing an excessive inflammatory reaction due to infection by an infectious agent and / or exposure to an allergen and / or exposure to an environmental provocative agent, where the pharmaceutical agent contains an agent for preventing (delaying), retarding modulating or reducing: (a) the production, activity and / or influence of one or more cytokines； and / or (b) the functionality of one or more cells that are cytokine targets； and / or (c) a pathological effect due to cells producing and / or activated cytokines. 2. The pharmaceutical agent of claim 1, wherein the inflammation is acute, subacute or chronic inflammation. The pharmaceutical agent of claim 2, wherein the inflammation is eosinophilic inflammation or inflammation with a delayed-type hypersensitivity reaction (DTH). The pharmaceutical agent of claim 1, wherein the pathological effect due to cells producing and / or activated cytokines is acute respiratory failure syndrome (ARDS), respiratory failure syndrome (RDS), or acute lung injury (ALI). The pharmaceutical agent according to claim 1, wherein the infectious agent is selected from influenza virus, hemophilic bacillus, SARS virus, adenovirus, respiratory syncytial virus. Streptococcus spp., Staphylococcus spp., Legionella spp., Pseudomonas spp., Klebsiella spp., Burkholderia spp., Pneumococcus spp., Mycobacterium spp., Chlamydia spp., Blastomyces spp., Cryptococcus spp. and Aspergillus spp. 6. The pharmaceutical agent of claim 1, wherein the allergen is an allergen that can cause asthma. Pharmaceutical a1. Фармацевтический агент для применения в лечении воспаления у индивидуума, склонного и/или испытывающего чрезмерную воспалительную реакцию вследствие инфицирования инфекционным агентом и/или воздействия аллергена и/или воздействия провоцирующего фактора окружающей среды, где фармацевтический агент содержит агент для предотвращения (упреждения), замедлен
